GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » bioAffinity Technologies Inc (NAS:BIAF) » Definitions » EPS (Diluted)

bioAffinity Technologies (bioAffinity Technologies) EPS (Diluted) : $-0.90 (TTM As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is bioAffinity Technologies EPS (Diluted)?

bioAffinity Technologies's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.26. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.90.

bioAffinity Technologies's EPS (Basic) for the three months ended in Dec. 2023 was $-0.26. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.90.

bioAffinity Technologies's EPS without NRI for the three months ended in Dec. 2023 was $-0.26. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.90.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.


bioAffinity Technologies EPS (Diluted) Historical Data

The historical data trend for bioAffinity Technologies's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

bioAffinity Technologies EPS (Diluted) Chart

bioAffinity Technologies Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
-2.67 -2.32 -1.81 -0.91

bioAffinity Technologies Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.20 -0.18 -0.20 -0.26 -0.26

Competitive Comparison of bioAffinity Technologies's EPS (Diluted)

For the Diagnostics & Research subindustry, bioAffinity Technologies's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


bioAffinity Technologies's PE Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, bioAffinity Technologies's PE Ratio distribution charts can be found below:

* The bar in red indicates where bioAffinity Technologies's PE Ratio falls into.



bioAffinity Technologies EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

bioAffinity Technologies's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-7.937-0)/8.748
=-0.91

bioAffinity Technologies's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-2.373-0)/9.337
=-0.25

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.90

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


bioAffinity Technologies  (NAS:BIAF) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


bioAffinity Technologies EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of bioAffinity Technologies's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


bioAffinity Technologies (bioAffinity Technologies) Business Description

Traded in Other Exchanges
N/A
Address
22211 W Interstate 10, Suite 1206, San Antonio, TX, USA, 78257
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company is involved in developing technologies that, in the future, will be able to detect and monitor diseases of the lung and other cancers and treat many cancers.
Executives
Roby Joyce director 22211 W INTERSTATE 10, SUITE 1206, SAN ANTONIO TX 78257
Xavier Trinidad Reveles officer: Chief Operating Officer 22211 W INTERSTATE 10, SUITE 1206, SAN ANTONIO TX 78257
Michael Philip Dougherty officer: Chief Financial Officer 2934 SCATTERED OAKS ST, SAN ANTONIO TX 78232
James Michael Edwards officer: Chief Financial Officer 30907 KEENELAND DRIVE, FAIR OAKS RANCH TX 78015
Peter S Knight director 6702 STEIN CIRCLE, #642, P.O. BOX 4138, PARK CITY UT 84060
Steven Girgenti director, officer: Executive Chairman C/O HEALTHWORLD CORP, 100 AVENUE OF THE AMERICAS, NEW YORK NY 10013
Robert A. Anderson director 70 DOPPLER, IRVINE CA 92618
Gary D Rubin director, 10 percent owner 2080 NW BOCA RATON BLVD, STE 2, BOCA RATON FL 33431
Stuart Diamond director 498 SEVENTH AVE, NEW YORK NY 10018
Maria Zannes director, officer: President, CEO 19702 BELLA LOMA, #6005, SAN ANTONIO TX 78256
Harvey Sandler Revocable Trust 10 percent owner 21170 N. E. 22ND COURT, NORTH MIAMI BEACH FL 33180
Mohsin Y Meghji director C/O LOUGHLIN MEGHJI + COMPANY, NEW YORK NY 10016
Vivienne I Rebel officer: EVP, Chief Sci. & Med. Officer 8922 APACHE TRAIL, SAN ANTONIO TX 78255
Timothy P Zannes officer: Secretary, EVP, Gen. Counsel 1510 VISTA LARGA CT. NE, ALBUQUERQUE NM 87106
Nathan M Perlmutter 10 percent owner 28 PARRISH POND LANE, SOUTHAMPTON NY 11968